We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Hyperhomocysteinemia inl-dopa treated Parkinson's disease patients: effect of cobalamin and folate administration.
- Authors
Lamberti, P.; Zoccolella, S.; Armenise, E.; Lamberti, S. V.; Fraddosio, A.; Mari, M.; Iliceto, G.; Livrea, P.
- Abstract
Homocysteine (Hcy) is a risk factor for vascular diseases, cognitive impairment and dementia.l-dopa treatment may represent an acquired cause of hyperhomocysteinemia (HHcy), as evidenced by studies in rats as well as in Parkinson's disease (PD) patients. Folate and cobalamin status also seems to influence the effects ofl-dopa on plasma Hcy levels; therefore B-vitamins supplementation has been proposed to reduce the HHcy inl-dopa treated PD patients. Plasma Hcy, folate, and cobalamin levels were evaluated in 20 PD patients treated withl-dopa in the baseline condition and following a 5-week period of treatment with cobalamin and folate; results were compared with 35 controls. Analysis of data revealed that Hcy levels were higher inl-dopa treated PD patients when compared with age- and sex-matched controls and that supplementation of the diet with cobalamin and folate is effective in reducing Hcy concentrations; these findings may have important implications in the treatment of PD patients who are potentially at risk for vascular diseases and cognitive impairment or dementia.
- Subjects
HOMOCYSTEINE; SULFUR amino acids; PARKINSON'S disease; PHENYLALANINE; AMINO acids; LOW-phenylalanine diet
- Publication
European Journal of Neurology, 2005, Vol 12, Issue 5, p365
- ISSN
1351-5101
- Publication type
Article
- DOI
10.1111/j.1468-1331.2004.00973.x